Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human papillomavirus vaccines: Why the time is right to implement immunization and surveillance programs in Canada.

Literature DB >> 19436510

Human papillomavirus vaccines: Why the time is right to implement immunization and surveillance programs in Canada.

Ameeta Singh¹, Tom Wong, Roberta I Howlett.

Abstract

Entities: Disease

Year: 2008 PMID： 19436510 PMCID： PMC2604776 DOI： 10.1155/2008/813065

Source DB: PubMed Journal: Can J Infect Dis Med Microbiol ISSN： 1712-9532 Impact factor: 2.471

× No keyword cloud information.

17 in total

1. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Authors: Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barbara Romanowski; Cecilia M Roteli-Martins; David Jenkins; Anne Schuind; Sue Ann Costa Clemens; Gary Dubin
Journal: Lancet Date: 2006-04-15 Impact factor: 79.321

2. THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?

Authors: A B HILL
Journal: Proc R Soc Med Date: 1965-05

3. Human papillomavirus infection among sexually active young women in the United States: Implications for developing a vaccination strategy.

Authors: Lisa E Manhart; King K Holmes; Laura A Koutsky; Troy R Wood; Donna L Kenney; Qinghua Feng; Nancy B Kiviat
Journal: Sex Transm Dis Date: 2006-08 Impact factor: 2.830

Review 4. Sex and HIV education programs: their impact on sexual behaviors of young people throughout the world.

Authors: Douglas B Kirby; B A Laris; Lori A Rolleri
Journal: J Adolesc Health Date: 2007-03 Impact factor: 5.012

5. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women.

Authors: Stan L Block; Terry Nolan; Carlos Sattler; Eliav Barr; Katherine E D Giacoletti; Colin D Marchant; Xavier Castellsagué; Steven A Rusche; Suzanne Lukac; Janine T Bryan; Paul F Cavanaugh; Keith S Reisinger
Journal: Pediatrics Date: 2006-11 Impact factor: 7.124

6. Screening for cervical disease in mature women: strategies for improvement.

Authors: Terence J Colgan; Aileen Clarke; Natalia Hakh; Allan Seidenfeld
Journal: Cancer Date: 2002-08-25 Impact factor: 6.860

7. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

Authors: Keith S Reisinger; Stan L Block; Eduardo Lazcano-Ponce; Rudiwilai Samakoses; Mark T Esser; Joanne Erick; Derek Puchalski; Katherine E D Giacoletti; Heather L Sings; Suzanne Lukac; Frances B Alvarez; Eliav Barr
Journal: Pediatr Infect Dis J Date: 2007-03 Impact factor: 2.129

8. Risk of female human papillomavirus acquisition associated with first male sex partner.

Authors: Rachel L Winer; Qinghua Feng; James P Hughes; Sandra O'Reilly; Nancy B Kiviat; Laura A Koutsky
Journal: J Infect Dis Date: 2008-01-15 Impact factor: 5.226

9. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada.

Authors: Marc Brisson; Nicolas Van de Velde; Philippe De Wals; Marie-Claude Boily
Journal: Vaccine Date: 2007-05-22 Impact factor: 3.641

10. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk.

Authors: Anil K Chaturvedi; Eric A Engels; Ethel S Gilbert; Bingshu E Chen; Hans Storm; Charles F Lynch; Per Hall; Froydis Langmark; Eero Pukkala; Magnus Kaijser; Michael Andersson; Sophie D Fosså; Heikki Joensuu; John D Boice; Ruth A Kleinerman; Lois B Travis
Journal: J Natl Cancer Inst Date: 2007-10-30 Impact factor: 13.506

4 in total